Jin Yang Pharmaceutical Co. Ltd (007370) - Total Assets
Based on the latest financial reports, Jin Yang Pharmaceutical Co. Ltd (007370) holds total assets worth ₩271.49 Billion KRW (≈ $183.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Jin Yang Pharmaceutical Co. Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Jin Yang Pharmaceutical Co. Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore 007370 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Jin Yang Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jin Yang Pharmaceutical Co. Ltd's total assets of ₩271.49 Billion consist of 17.2% current assets and 82.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.8% |
| Accounts Receivable | ₩23.06 Billion | 8.6% |
| Inventory | ₩15.62 Billion | 5.8% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.39 Billion | 2.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jin Yang Pharmaceutical Co. Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jin Yang Pharmaceutical Co. Ltd's current assets represent 17.2% of total assets in 2025, a decrease from 58.7% in 2014.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2025, down from 8.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Jin Yang Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Jin Yang Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Jin Yang Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 2.58 | 2.01 |
| Quick Ratio | 0.35 | 1.76 | 1.45 |
| Cash Ratio | 0.00 | 0.17 | 0.17 |
| Working Capital | ₩-43.56 Billion | ₩27.92 Billion | ₩14.08 Billion |
Jin Yang Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Jin Yang Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.32 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.7% |
| Total Assets | ₩267.81 Billion |
| Market Capitalization | $33.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jin Yang Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jin Yang Pharmaceutical Co. Ltd's assets grew by 17.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jin Yang Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual total assets of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩267.81 Billion ≈ $181.49 Million |
+17.68% |
| 2024-12-31 | ₩227.57 Billion ≈ $154.22 Million |
+89.79% |
| 2023-12-31 | ₩119.91 Billion ≈ $81.26 Million |
+4.77% |
| 2022-12-31 | ₩114.44 Billion ≈ $77.56 Million |
+16.18% |
| 2021-12-31 | ₩98.50 Billion ≈ $66.75 Million |
+44.69% |
| 2020-12-31 | ₩68.08 Billion ≈ $46.13 Million |
-0.29% |
| 2019-12-31 | ₩68.28 Billion ≈ $46.27 Million |
-2.55% |
| 2018-12-31 | ₩70.06 Billion ≈ $47.48 Million |
-5.13% |
| 2017-12-31 | ₩73.85 Billion ≈ $50.05 Million |
-3.82% |
| 2016-12-31 | ₩76.78 Billion ≈ $52.04 Million |
-11.64% |
| 2015-12-31 | ₩86.90 Billion ≈ $58.89 Million |
+13.33% |
| 2014-12-31 | ₩76.68 Billion ≈ $51.97 Million |
-- |
About Jin Yang Pharmaceutical Co. Ltd
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports i… Read more